Top

Published in:

01-10-2014 | Research

Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences

Authors: Péter Kovács, Gitta Pánczél, Kinga Borbola, Gabriella Juhász, Gabriella Liszkay

Published in: Pathology & Oncology Research | Issue 4/2014

Abstract

Immuntherapies are frequently accompanied by psychological side effects. Our goals were to detect the changes of psychological factors (depression, anxiety) among melanoma patients during ipilimumab treatment. Ten ipilimumab treated melanoma patients (Group 1.) and 18 low-dose interferon-alpha treated patients (Group 2.) were compared. In our longitudinal study we measured depression (Zung Self-Rating Depression Scale) and anxiety (State-Trait Anxiety Inventory, STAI). Psychological status was tested four times: in every 3 week during ipilimumab treatment according to the relevant treatment protocol and at baseline, 1st, 3rd and 6th month of interferon therapy. No significant differences were detected at different timepoints in the level of depression or in the anxiety scale in Group 1. However significant increase of depression was found in Group 2 during the 6 months of the study. Increased levels of anxiety were found in the second timepoint in both treatment groups. This increase was only temporary and the level of anxiety returned to the baseline. In our sample no measurable psychological differences were detectable during the 12 weeks treatment period of ipilimumab. Ipilimumab seems to have fewer psychological side-effects compared to other immune therapies.

Petrella T, Verma S, Spithoff K, McCready D (2012) Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol 26(4):413–423CrossRef

Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(85):1–7

Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501PubMedCrossRef

Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27(1):3–9PubMedCrossRef

Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012PubMedCrossRef

Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587–595PubMedCrossRef

Rusthoven JJ, Quirt IC, Iscoe NA et al (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083–2090PubMed

Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166PubMed

Verma S, Quirt I, McCready D, Bak K, Charrette M, Iscoe N (2006) Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106:1431–1442PubMedCrossRef

10.

Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526PubMedCrossRef

11.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCrossRefPubMedCentral

12.

Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–update. Eur J Cancer 48:2375–2390PubMedCrossRef

13.

Wheatley K, Ives N, Eggermont A, on behalf of International Malignant Melanoma Collaborative Group et al (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 25(suppl 18):8526

14.

Friebe A, Horn M, Schmidt F et al (2010) Dose-dependent development of depressive symptoms during adjuvant interferon treatment of patients with malignant melanoma. Psychosomatics 51:466–473PubMed

15.

Bonaccorso S, Marino V, Biondi M et al (2002) Depression induced by treatment with interferon- in patients affected by hepatitis C virus. J Affect Disord 72:237–241PubMedCrossRef

16.

Borden EC, Parkinson D (1998) A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 25:3–8PubMed

17.

Dieperink E, Willenbring M, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon: a review. Am J Psychiatry 157:867–876PubMedCrossRef

18.

Dafny N, Prieto-Gomez B, Reyes-Vazquez C (1985) Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 9:1–12PubMedCrossRef

19.

Schaefer M, Engelbrecht MA, Gut O et al (2002) Interferon (IFN) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26:731–746PubMedCrossRef

20.

Zung WWK (1965) A self-rating depression scale. Arch Gen Psychiatry 12:63–70PubMedCrossRef

21.

Simon A (1994) A Zung-féle Önértékelő Depresszió Skála. In: Mérei F, Szakács F (eds) Pszichodiagnosztikai Vademecum. Nemzeti Tankönyvkiadó, Budapest, pp 180–185

22.

Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto

23.

Sipos K, Sipos M (1983) The development and validation of the Hungarian form of the STAI. In: Spielberger CD, DiazGuerro R (eds) Cross cultural anxiety, 2. Hemisphere Publishing Corporation, Washington-London, pp 51–61

24.

Caldwell RA, Pearson JL, Chin RJ (1987) Stress-moderating effects: social support in the context of gender and locus of control. Personal Soc Psychol Bull 13(1):5–17CrossRef

25.

Rychetnick L, McCaffery K, Morton R, Irwing L (2012) Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psychooncology 22(4):721–736CrossRef

26.

Kasparian AN, Sansom-Daly U, McDonald RP, Meiser B, Butow PN, Mann GJ (2012) The nature and structure of psychological distress in people at high risk for melanoma: a factor analytic study. Psychooncology 21:845–856CrossRef

27.

Meyer F, Ehrlich M, Peteet J (2009) Psycho-oncology: a review for the general psychiatrist. FOCUS 7:317–331

28.

Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients. Cancer 115:5349–5361PubMedCrossRef

29.

Fawzy IF, Fawzy NW, Hyun CS et al (1993) Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50:681–689PubMedCrossRef

30.

Eggermont AM, Suciu S, Santinami M, EORTC Melanoma Group et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 372(9633):117–126PubMedCrossRef

31.

Trask P, Paterson A, Esper P et al (2004) Longitudinal course of depression, fatigue, and quality of life in patients with high-risk melanoma receiving adjuvant interferon. Psychooncology 13:526–536PubMedCrossRef

32.

Eggermont AMM, Suciu S, MacKie R, for the EORTC Melanoma Group et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366:1189–1196PubMedCrossRef

33.

Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. Lancet 351:1905–1910PubMedCrossRef

34.

Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988–1000PubMedCrossRef

35.

Licinio J, Kling MA, Hauser P (1998) Cytokines and brain function: relevance to interferon-alpha induced mood and cognitive changes. Semin Oncol 25(suppl 1):S30–S38

36.

Reiche EMV, Nunes SOV, Morimoto HK (2004) Stress, depression, the immune system and cancer. Lancet 5:617–625PubMedCrossRef

37.

Musselmann DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by highdose interferon alpha. N Engl J Med 344:961–966CrossRef

38.

Almeida AG, Guindalini C, Batista-Neves S et al (2010) Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 32:401–405CrossRef

39.

Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trends Immunol 27:24–31PubMedCrossRefPubMedCentral

40.

Heinze S, Egberts F, Rötzer S et al (2010) Depressive mood changes and psychiatric symptoms. J Immunother 33:106–114PubMedCrossRef

Title: Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences
Authors: Péter Kovács
Gitta Pánczél
Kinga Borbola
Gabriella Juhász
Gabriella Liszkay
Publication date: 01-10-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9777-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Tricellulin Expression and its Prognostic Significance in Primary Liver Carcinomas

Activation of Hedgehog Signaling Pathway in Human Non-small Cell Lung Cancers

Intravenous Administration of a Single-Dose Free-Circulating DNA of Colitic Origin Improves Severe Murine DSS-Colitis

The Role of Protein p16INK4a in Glottic Laryngeal Squamous Cell Carcinoma

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

WWP2: A Multifunctional Ubiquitin Ligase Gene

Keynote webinar | Spotlight on antibody–drug conjugates in cancer